MGX 8-K 2026-11-10

Metagenomi Therapeutics, Inc. (MGX) 8-K dated 2026-11-10 — accession 0001193125-26-455436.

Metagenomi Therapeutics, Inc. (MGX) is a biotechnology company listed on NASDAQ.

Metagenomi Therapeutics, Inc. filed a 8-K on 2026-11-10. Accession 0001193125-26-455436.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported MGX revenue for 2025-12-31 was $25.2M. Net income was -$87.9M. Revenue was down 51.8% from 2024-12-31 to 2025-12-31. MGX currently screens at market cap $44.4M.

Not investment advice. The MGX SEC hub lists recent forms. The stock page is the research view.